C. Ola Landgren, M.D. Chief of the Myeloma Service in the Division of Hematologic Oncology at Memorial Sloan Kettering Cancer Center Discusses MRD Testing: Primary Endpoint For Drug Development at Lymphoma & Myeloma on October 18, 2018.
Advertisement